title: Optimal antithrombotic treatment in patients with atrial fibrillation and coronary stents: an update.
abstract: The optimal antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention (PCI) is still debated. This review is an update of a previous review and aims to summarize new published data regarding the management of this group of atrial fibrillation patients.
  
  
  
  Recent data report an underuse of oral anticoagulation in patients with atrial fibrillation undergoing PCI while indicated. However, tools for risk assessment and thus better guidance for decision-making are lacking, especially for elderly atrial fibrillation patients. New evidence suggests that the combination of oral anticoagulation and clopidogrel without aspirin may improve clinical outcomes in comparison with triple therapy; however, there is little data regarding the role of non-vitamin K oral anticoagulants and newer P2Y12 inhibitors in these regimens.
  
  
  
  Despite accumulating data on the assessment of bleeding and thrombotic risk, the management of elderly atrial fibrillation patients, new treatment regimens, and the role of more potent antithrombotic agents, the optimal antithrombotic therapy for patients with atrial fibrillation after PCI is still unclear. In the meantime, careful assessment of both thrombotic and bleeding risk and individualized decision-making are paramount to ensure the best patient outcomes.
authors.affiliation: aDepartment of Cardiology, St Antonius Hospital, Nieuwegein bDepartment of Cardiology, Amphia Hospital Breda, Breda, The Netherlands.
authors.forename: Naoual
authors.initials: N
authors.lastname: Bennaghmouch
authors.forename: Willem J M
authors.initials: WJ
authors.lastname: Dewilde
authors.forename: Jurrien M
authors.initials: JM
authors.lastname: Ten Berg
mesh_terms: D000925:Anticoagulants / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000628:therapy*; D004359:Drug Therapy, Combination; D006801:Humans; D062645:Percutaneous Coronary Intervention / Q000379:methods*; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000627:therapeutic use*; D015607:Stents
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors